Genetically engineered fixed K562 cells: potent “off-the-shelf” antigen-presenting cells for generating virus-specific T cells

Abstract

Fixed gene-modified K562 can serve as effective aAPC to expand CMV-specific cytotoxic T lymphocytes for therapeutic use in patients after stem cell transplantation. Our findings have implications for broader understanding of the immune evasion mechanisms used by leukemia and other tumors.

Toward precision manufacturing of immunogene T-cell therapies

“…In comparison with commercially available antibodycoated expansion beads, however, cell-based APC platforms require the generation and maintenance of cell banks under good manufacturing practice (GMP) regulations. Furthermore, K562 cells may inhibit T-cell expansion by producing soluble factors [76,77], suggesting that further engineering is needed to improve their stimulatory capacities.…”

Effect of Cellular-Based Artificial Antigen Presenting Cells Expressing ICOSL, in T-cell Subtypes Differentiation and Activation

“…The other cell-based T-cell activation strategy is Artificial Antigen Presenting Cells (aAPCs) 15,16 . Irradiated or fixed K562 based GMP grade aAPC systems introduced recently with satisfying efficacy [17][18][19] even in T-cell activation and manipulation systems or direct use as new approaches in anti-cancer strategies 19 , There are variety of molecules serving co-stimulatory effect on APCs but the CD28 family molecules are the most important one that can affect the kind and nature of the T-cells responses 20,21 ; Of them, ICOS molecule, member of CD28 superfamily, serve specific characteristics. Despite permanent expression of CD28 on T-cells, inducible co-stimulator, express following T-cell activation 22 .…”

“…al. work 18 . WT K562 cells were cultured at RPMI-1640 supplemented by 10% FBS and 100IU/ml Penicillin and 100ug/ml Streptomycin, at 37 C and 5% Co2.…”